DHR Danaher Corporation
$200.14▼ -0.19%
Healthcare
Other
After hours
$200.14▲ +0.00%
Sep 11, 4:51 PM ET
Volume 3.63M
Avg Volume (10D) 2.99M
Key Metrics & Fundamentals
Market Cap
$140.70B
P/E Ratio
35.7
Div Yield
0.80%
52W Range
160.93 - 242.80
% vs 50 MA
-1.11%
% vs 200 MA
-1.11%
RSI-14
41.4
MACD Histogram
-2.0800
Beta (1Y vs SPY)
0.44
Free Cash Flow
$1.27B
Gross Rev
$6.27B
Gross Profit
$3.61B
EBITDA
$1.85B
COGS
$2.65B
Operating Exp
$2.48B
Operating Income
$1.13B
EBIT
$1.13B
Pretax Income
$1.08B
Net Income
$870.00M
EPS (Diluted)
1.23
Price & Volume History
Loading chart…
Recent News
3 Reasons DHR is Risky and 1 Stock to Buy Instead
StockStory · Sep 10, 2026 2:33 PM
Thermo Fisher, Danaher Could Log Mid-Single-Digit Organic Revenue Growth in 2027, UBS Says
MT Newswires · Sep 9, 2026 5:55 PM
ILMN Stock Keeps Climbing. Should You Climb On?
Trefis · Sep 8, 2026 7:37 PM
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others
GlobeNewswire · Sep 8, 2026 2:49 PM
Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?
Zacks · Sep 4, 2026 11:49 AM
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
GlobeNewswire · Sep 4, 2026 9:48 AM
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?
Zacks · Sep 3, 2026 3:30 PM
Danaher (DHR) Seen Deftly Navigating AI Integration
Insider Monkey · Sep 3, 2026 2:54 PM
Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale
PR Newswire · Sep 3, 2026 12:30 PM
Baird Adjusts Price Target on Danaher to $238 From $232, Keeps Outperform Rating
MT Newswires · Sep 3, 2026 11:37 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See DHR's money flow as a full page
Social Sentiment
Avg +0.63 · 2 posts
TradeDiscussionManaged account, many winners but no profit taken
r/investing · Dec 10, 2024
Substantial gain described, generally positive.
positive
+0.65
NVDA Ranked Among the Top 10 S&P 500 Performing Stocks Since IPO
r/stocks · Jun 4, 2024
DHR's inclusion in the top 8 performers suggests a positive outlook on the stock's performance.
positive
+0.60
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.